In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

The California Institute for Regenerative Medicine (CIRM) has approved awarding $27 million through three grants across the state to create a network of Community Care Centers of Excellence (CCCEs).

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Cryoport, Inc.  ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems, a Cryoport company, has ...

Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build momentum and ...

Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of ...

The basal cell nevus syndrome market is expected to witness steady growth driven by increasing awareness, advances in targeted therapies, and the development of novel hedgehog pathway inhibitors.

NLS Pharmaceutics Ltd. ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. ("Kadimastem"), a clinical-stage ...